Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) reached a new 52-week low during trading on Thursday . The company traded as low as $2.01 and last traded at $2.23, with a volume of 1571 shares changing hands. The stock had previously closed at $2.36.

TRIL has been the subject of a number of recent analyst reports. HC Wainwright set a $10.00 price objective on Trillium Therapeutics and gave the company a “buy” rating in a report on Thursday, November 15th. Zacks Investment Research upgraded Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Tuesday, October 23rd.

The firm has a market cap of $33.05 million, a P/E ratio of -0.57 and a beta of 2.39. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.01.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRIL. Wealth Alliance Advisory Group LLC bought a new stake in Trillium Therapeutics in the third quarter valued at about $126,000. Stanley Laman Group Ltd. increased its holdings in shares of Trillium Therapeutics by 26.7% in the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock worth $823,000 after acquiring an additional 28,907 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Trillium Therapeutics by 245.3% in the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock worth $864,000 after acquiring an additional 102,300 shares in the last quarter. Morgan Stanley increased its holdings in shares of Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after acquiring an additional 71,860 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its holdings in shares of Trillium Therapeutics by 25.0% in the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock worth $3,071,000 after acquiring an additional 102,440 shares in the last quarter. Institutional investors and hedge funds own 47.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Trillium Therapeutics (TRIL) Sets New 1-Year Low at $2.01” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/trillium-therapeutics-tril-sets-new-1-year-low-at-2-01/2671159.html.

Trillium Therapeutics Company Profile (NASDAQ:TRIL)

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Further Reading: Are all No-Load Funds Equal?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.